Disophrol® Syrup versus Rinomar® Syrup in the Treatment of Allergic Rhinitis in Children

1982 ◽  
Vol 10 (6) ◽  
pp. 426-430 ◽  
Author(s):  
Friedrich Horak
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Adverse Reactions ◽  
Nasal Secretion ◽  
Response To Therapy ◽  
Efficacy And Safety ◽  
Patient Response ◽  
Treatment Groups ◽  
Significant Difference ◽  
Single Blind

In this single-blind study, the efficacy and safety of Disophrol® Syrup was compared to Rinomar® Syrup in seventy-eight paediatric patients with seasonal allergic rhinitis. Patients took 5–10 ml of the randomly assigned medication three to four times daily for a 2-week period. Severity of nasal obstruction, nasal secretion and mucosal swelling was graded and patient response to each week of therapy evaluated. An overall favourable response to Disophrol® Syrup was observed in thirty-one out of thirty-five (89%) patients and in thirty out of thirty-five (86%) patients in the Rinomar® group. No statistically significant difference in patient response to therapy between treatment groups was noted and no mentionable adverse reactions were reported.

Azatadine Maleate/Pseudoephedrine Sulfate Repetabs versus Placebo in the Treatment of Severe Seasonal Allergic Rhinitis

1980 ◽  
Vol 8 (6) ◽  
pp. 391-394 ◽  
Author(s):  
Juan Carlos Tarasido
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Marked Improvement ◽  
Adverse Reactions ◽  
Active Drug ◽  
Signs And Symptoms ◽  
Double Blind Study ◽  
Efficacy And Safety ◽  
Combination Drug ◽  
Double Blind

The symptoms of seasonal allergic rhinitis can be alleviated by the use of an antihistamine and a decongestant. The efficacy and safety of the combination of azatadine maleate and pseudoephedrine sulfate were examined in this double-blind study comparing active drug to placebo. While 74% of the patients administered the combination drug showed marked improvement in the signs and symptoms of seasonal allergic rhinitis, only 29% of patients receiving placebo demonstrated improvement. Adverse reactions were mild and transient.

scholarly journals Potential Immuno-modulatory activity of Probiotics containing Lactobacillusacidophilus and Lacobacilluscasei to increase the ratio of IFN γ/IL-4 in patients with Allergic Rhinitis

2018 ◽  
Vol 18 (1) ◽  
pp. 42-45
Author(s):  
Andriana Tjitria Widi Wardani ◽  
Wiratno ◽  
Dina Fatmawati
Keyword(s):  
Allergic Rhinitis ◽  
Medical Science ◽  
Control Group ◽  
Placebo Control ◽  
Treatment Groups ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Ifn Γ ◽  
And Control ◽  
Single Blind

Aims: This study aimed to determine the effect of probiotic combination on ratio of IFN-γ: IL-4 levels in patients with allergic rhinitis. Materials and methods: Single blind, randomized controlled trial.This study included 40 patients with severe allergic rhinitis according to WHO criteria. This study used 2 treatment groups with probiotics and placebo control group. IFN γ and IL-4 levels were evaluated using ELISA method. Data were analyzed using paired T test with 95% confidence intervals Results and Discussion: In the treatment group, the levels of IFN-γ increased significantly (p<0.05).In contrast, IL-4 levels decreased significantly(p<0.05). There was a significant difference between the IFN-γ ratio: IL-4 treatment and control group (p <0.05). Conclusion: The administration of combination of probiotics can improve the levels of IFN-γ/ IL-4 in patients with moderate to severe allergic rhinitis. Bangladesh Journal of Medical Science Vol.18(1) 2019 p.42-45

scholarly journals Efficacy and Safety of Olopatadine/Mometasone Combination Nasal Spray in Patients With Seasonal Allergic Rhinitis

2018 ◽  
Vol 141 (2) ◽  
pp. AB173 ◽  
Author(s):  
Frank C. Hampel ◽  
Andrew J. Pedinoff ◽  
Robert L. Jacobs ◽  
Aurora Breazna ◽  
Cynthia F. Caracta ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Spray ◽  
Seasonal Allergic Rhinitis ◽  
Efficacy And Safety

scholarly journals Randomized Trial of Trimethoprim-Sulfamethoxazole versus Pyrimethamine-Sulfadiazine for Therapy of Toxoplasmic Encephalitis in Patients with AIDS

1998 ◽  
Vol 42 (6) ◽  
pp. 1346-1349 ◽  
Author(s):  
Donato Torre ◽  
Salvatore Casari ◽  
Filippo Speranza ◽  
Alessandra Donisi ◽  
Giampietro Gregis ◽  
...  
Keyword(s):  
Bacterial Infections ◽  
Adverse Reactions ◽  
Common Adverse Event ◽  
Toxoplasmic Encephalitis ◽  
Efficacy And Safety ◽  
Acute Therapy ◽  
Valuable Alternative ◽  
Significant Difference ◽  
To Receive ◽  
Present Pilot Study

ABSTRACT The aim of the present pilot study was to compare the efficacy and safety of trimethoprim (TMP) and sulfamethoxazole (SMX) with those of the standard therapy pyrimethamine (P)-sulfadiazine (S) for the treatment of toxoplasmic encephalitis in patients with AIDS. This was a pilot, multicenter, randomized, and prospective study. Patients were randomly assigned to receive TMP (10 mg/kg of body weight/day) and SMX (50 mg/kg/day) or P (50 mg daily) and S (60 mg/kg/day) as acute therapy (for 4 weeks) and then as maintenance therapy for 3 months at half of the original dosage. Seventy-seven patients were enrolled and randomized to the study: 40 patients were treated with TMP-SMX and 37 were treated with P-S. There was no statistically significant difference in clinical efficacy during acute therapy. In contrast, patients randomized to TMP-SMX appeared more likely to achieve a complete radiologic response after acute therapy. Adverse reactions were significantly more frequent in patients treated with P-S, and skin rash was the most common adverse event noted in these patients. In conclusion, the results of the study suggest that TMP-SMX appears to be a valuable alternative to P-S, in particular in patients with opportunistic bacterial infections.

Efficacy and Safety of Mizolastine in Seasonal Allergic Rhinitis

1996 ◽  
Vol 76 (2) ◽  
pp. 163-168 ◽  
Author(s):  
Francisque Leynadier ◽  
Jean Bousquet ◽  
Margarita Murrieta ◽  
Pierre Attali
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Efficacy And Safety

scholarly journals The Efficacy and Safety of Nabufen and Sufentanil in the Prevention of Visceral Pain After Gynecological Laparoscopic Surgery: A Randomised Controlled Trial

2020 ◽  
Author(s):  
Xiaoxia Gu ◽  
Jingjing Wang ◽  
Huihua Liao ◽  
Jian Mo ◽  
Weiming Huang ◽  
...  
Keyword(s):  
Laparoscopic Surgery ◽  
Adverse Reactions ◽  
Visceral Pain ◽  
Sedation Score ◽  
Efficacy And Safety ◽  
Significant Difference ◽  
Group A ◽  
Group B ◽  
Group D ◽  
Ramsay Sedation Score

Abstract Background: To compare the efficacy and safety of different compatibility schemes in the prevention of visceral pain after gynecological laparoscopic surgery. Methods: from April 2019 to April 2020, patients undergoing elective gynecological laparoscopic surgery in our hospital were randomly divided into four groups: group A: sufentanil 3 μ g / kg; group B: low-dose nalbuphine group: 0.1 mg / kg of nabufen + 3 μ g / kg of sufentanil; group C: medium dose of nabufen group: 1 mg / kg of nabufen + 2 μ g / kg of sufentanil; group D: high-dose nabufen 2 There were 30 cases in each group. The degree of pain and the number of adverse reactions at 2, 4, 8, 12, 24 and 48 hours after operation were observed and recorded. The number and dosage of morphine used as a remedial analgesic were recorded. The pain degree was assessed by visual analogue scale (VAS). The total amount of analgesic pump used, the total number of times of pressing and the effective times of pressing were recorded. The adverse reactions included respiratory depression, nausea and vomiting, drowsiness, restlessness and skin The skin itches. Results: the analgesic effect of group B was similar to that of group A, and there was no significant difference in the number of invalid pressing, total pressing times and rescue analgesia rate (P > 0.05), while the invalid pressing times, total pressing times and remedial analgesia rate of group C and group D were significantly lower than those of group A (P < 0.05). There was no significant difference between group C and group D in the number of invalid compressions, the total number of compressions and the rate of remedial analgesia (P > 0.05), suggesting that increasing the dose of nalbuphine could not significantly increase the analgesic effect. The incidence of postoperative nausea and vomiting, skin pruritus, lethargy and Ramsay Sedation score in group B and group C were significantly lower than those in group A (P < 0.05). Ramsay Sedation score and incidence of drowsiness were lower than those in group D, which indicated that the incidence of adverse reactions was higher in group D than group B and group C.Conclusion: the combination of 1 mg / kg nabufen and 2 μ g / kg sufentanil is a safe and effective combination scheme for the prevention of visceral pain after gynecological laparoscopic surgery with small adverse reactions.Trial registration: http://www.chictr.org.cn/showproj.aspx?proj=40635Registration number：ChiCTR1900025076 . Prospectively registered on 10 August 2019.

1009 Efficacy and safety of fexofenadine HCl in fall seasonal allergic rhinitis

1996 ◽  
Vol 97 (1) ◽  
pp. 435-435 ◽  
Author(s):  
D TINKELMAN ◽  
C FALLIERS ◽  
E BRONSKY ◽  
H KAISER ◽  
J MASON
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Efficacy And Safety ◽  
Fexofenadine Hcl

Efficacy and safety of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with seasonal allergic rhinitis

2012 ◽  
Vol 33 (5) ◽  
pp. 386-396 ◽  
Author(s):  
Julius H. van Bavel ◽  
Paul H. Ratner ◽  
Niran J. Amar ◽  
Frank C. Hampel ◽  
Amy Melchior ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Beclomethasone Dipropionate ◽  
Daily Treatment ◽  
Efficacy And Safety ◽  
Once Daily

A Comparison of Aqueous Suspensions of Budesonide Nasal Spray (128 μg and 256 μg Once Daily) and Fluticasone Propionate Nasal Spray (200 μg Once Daily) in the Treatment of Adult Patients with Seasonal Allergic Rhinitis

1997 ◽  
Vol 11 (4) ◽  
pp. 323-330 ◽  
Author(s):  
Martin A. Stern ◽  
Ronald Dahl ◽  
Lars P. Nielsen ◽  
Bente Pedersen ◽  
Camilla Schrewelius
Keyword(s):  
Allergic Rhinitis ◽  
Fluticasone Propionate ◽  
Nasal Spray ◽  
Seasonal Allergic Rhinitis ◽  
Adult Patients ◽  
Once Daily ◽  
Treatment Groups ◽  
Runny Nose ◽  
Aqueous Suspensions ◽  
Symptom Scores

The efficacy of aqueous suspensions of budesonide nasal spray and fluticasone propionate nasal spray, in the treatment of seasonal allergic rhinitis, was compared in a large, placebo-controlled, two-center study. A 1-week baseline period was followed by a 4- to 6-week treatment period during which 635 adult patients, aged 18–72 years, were randomized to receive either placebo, budesonide 128 μg, or 256 μg once daily, or fluticasone propionate, 200 μg once daily. Nasal and eye symptoms, overall treatment efficacy and safety assessments were made during the study period. Combined, as well as individual, nasal symptoms were significantly improved in all three active treatment groups compared with placebo therapy. Treatment with 256 μg/day of budesonide was found to be significantly more effective in reducing the sneezing score compared with 200 μg/day of fluticasone propionate. Analysis of symptom scores on days when the pollen count was greater than 10 grains/m3 revealed 256 μg/day of budesonide therapy to be significantly more effective in reducing combined symptom scores as well as the individual scores for sneezing and runny nose, compared with 200 μg/day fluticasone propionate. The higher dose of budesonide (256 μg/day) was also more effective than the lower dose (128 μg/day) in reducing sneezing scores and statistical significance was almost reached for the reduction in combined symptom and runny nose scores. Substantial or total control of symptoms was achieved by 31.4%, 85.3%, 88.4%, and 81.9% of patients receiving placebo, 128 μg/day of budesonide, 256 μg/day of budesonide, and 200 μg/day of fluticasone propionate, respectively. The incidence of adverse events was low in all treatment groups. In conclusion, both budesonide and fluticasone propionate treatments were effective and well-tolerated in the treatment of seasonal allergic rhinitis. However, 256 μg/day of budesonide tended to be more effective than 200 μg/day of fluticasone propionate and 128 μg/day of budesonide, especially when patients were exposed to a higher pollen load.

Sign in / Sign up

Export Citation Format

Share Document